The Experts below are selected from a list of 108 Experts worldwide ranked by ideXlab platform
Brian Berman - One of the best experts on this subject based on the ideXlab platform.
-
Safety and Efficacy of Aminolevulinic Acid 10% Topical Gel versus Aminolevulinic Acid 20% Topical Solution Followed by Blue-light Photodynamic Therapy for the Treatment of Actinic Keratosis on the Face and Scalp: A Randomized, Double-blind Study.
The Journal of clinical and aesthetic dermatology, 2019Co-Authors: Mark S. Nestor, Brian Berman, Jigesh Patel, Alec LawsonAbstract:Objective: Photodynamic therapy (PDT) using 10% 5-aminolevulinic acid (ALA) gel (GEL) has been shown to be highly effective for treating actinic keratosis (AK) but has only been studied using red-light activation. The goal of this study was to compare GEL and a 20% ALA solution (SOL) using blue-light activation under typical clinical conditions. Design: This double-blind, split-face study randomized subjects to GEL or SOL application to contiguous 25cm2 fields containing 4 to 8 AK lesions on either side of the face or scalp (no curettage, 1-hour incubation, no occlusion) followed by blue light exposure (1,000 seconds, 417nm, 10J/cm2). Participants: Forty adult subjects were treated on either the face (n=20) or scalp (n=20). Measurements: Primary outcomes included change in baseline AK lesions. Secondary outcomes included Local Skin Reaction (LSR) scores and visual analog scale (VAS) pain scores. Results: Lesions treated with GEL were 97.1 percent cleared at Day 84 versus 94.9 percent for lesions treated with SOL (p
-
Assessment of Local Skin Reactions with a sequential regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients with actinic keratosis.
Clinical cosmetic and investigational dermatology, 2014Co-Authors: Gary Goldenberg, Brian BermanAbstract:Lesion-directed and field-directed therapies are used to treat actinic keratosis (AK). Therapeutic approaches that combine both types of therapies may improve the successful elimination of AKs. A randomized, double-blind, vehicle-controlled study evaluated the safety, tolerability, and efficacy of topical field treatment with ingenol mebutate gel, 0.015%, after cryosurgery to AKs on the face and scalp. Patients with 4-8 visible discrete AKs in a 25-cm(2) contiguous area received cryosurgery of all AKs at baseline. After a 3-week healing period, patients applied ingenol mebutate gel, 0.015%, or vehicle gel once daily for 3 consecutive days to the treatment area. The incidence, severity, and time course of the development and resolution of Local Skin Reactions were measured from baseline to week 11. Local Skin Reactions peaked shortly after completion of ingenol mebutate treatment and generally resolved within 2 weeks. The mean (95% confidence interval) composite score (maximum range, 0-24) for these Reactions was higher in patients with treatment of AKs on the face, 9.3 (8.5-10.1), as compared with the scalp, 5.8 (4.3-7.4). Erythema and flaking/scaling were the major contributors to the composite Local Skin Reaction score. These results show that Local Skin Reactions associated with ingenol mebutate treatment of the face or scalp are well tolerated after recent cryosurgery.
Mark Lebwohl - One of the best experts on this subject based on the ideXlab platform.
-
relationship between severity of the Local Skin Reactions and the rate of Local Skin Reaction resolution in patients treated with ingenol mebutate gel
Clinical Cosmetic and Investigational Dermatology, 2016Co-Authors: Shelbi Jim C On, Kim Mark Knudsen, Torsten Skov, Mark LebwohlAbstract:BACKGROUND: Ingenol mebutate gel is a topical field treatment for actinic keratosis (AK). The treatment elicits application-site Reactions in most patients. This analysis evaluated the relationship between the severity of Reactions and the speed of their resolution. METHODS: Patients in Phase III studies were treated for AKs on the face (n=218), scalp (n=56), and trunk and extremities (n=209). All of the patients were treated with either ingenol mebutate gel 0.015% once daily for three consecutive days (face/scalp) or ingenol mebutate gel 0.05% once daily for two consecutive days (trunk/extremities). Local Skin Reactions (LSRs) were assessed on a 5-point scale from 0 to 4 in six categories, yielding composite scores in the range of 0 to 24. RESULTS: The composite LSR score on the day after the last application of ingenol mebutate gel was an important predictor of the speed of resolution of LSRs. The rate of resolution was greatest for AKs treated on the face, followed by the scalp, and then the trunk and extremities. All patients were expected to have minimal LSR scores for the face and scalp at 2 weeks, and for the trunk and extremities at 4 weeks. CONCLUSION: The absolute reduction in LSR scores was proportional to the composite LSR score on the day after the last application of ingenol mebutate gel treatment. The rate of resolution for LSRs was dependent on the anatomic site treated as well as the day 4 composite score.
Alec Lawson - One of the best experts on this subject based on the ideXlab platform.
-
Safety and Efficacy of Aminolevulinic Acid 10% Topical Gel versus Aminolevulinic Acid 20% Topical Solution Followed by Blue-light Photodynamic Therapy for the Treatment of Actinic Keratosis on the Face and Scalp: A Randomized, Double-blind Study.
The Journal of clinical and aesthetic dermatology, 2019Co-Authors: Mark S. Nestor, Brian Berman, Jigesh Patel, Alec LawsonAbstract:Objective: Photodynamic therapy (PDT) using 10% 5-aminolevulinic acid (ALA) gel (GEL) has been shown to be highly effective for treating actinic keratosis (AK) but has only been studied using red-light activation. The goal of this study was to compare GEL and a 20% ALA solution (SOL) using blue-light activation under typical clinical conditions. Design: This double-blind, split-face study randomized subjects to GEL or SOL application to contiguous 25cm2 fields containing 4 to 8 AK lesions on either side of the face or scalp (no curettage, 1-hour incubation, no occlusion) followed by blue light exposure (1,000 seconds, 417nm, 10J/cm2). Participants: Forty adult subjects were treated on either the face (n=20) or scalp (n=20). Measurements: Primary outcomes included change in baseline AK lesions. Secondary outcomes included Local Skin Reaction (LSR) scores and visual analog scale (VAS) pain scores. Results: Lesions treated with GEL were 97.1 percent cleared at Day 84 versus 94.9 percent for lesions treated with SOL (p
Benjawan Tuetun - One of the best experts on this subject based on the ideXlab platform.
-
Assessment of Angelica sinensis (Oliv.) Diels as a repellent for personal protection against mosquitoes under laboratory and field conditions in northern Thailand
Parasites & Vectors, 2016Co-Authors: Danita Champakaew, Anuluck Junkum, Jitrawadee Intirach, Roongtawan Muangmoon, Arpaporn Chansang, Udom Chaithong, Atchariya Jitpakdi, Doungrat Riyong, Anchalee Wannasan, Benjawan TuetunAbstract:BackgroundAngelica sinensis (Oliv.) hexane extract (AHE) has been reported as a proven and impressive repellent against laboratory-reared female Aedes aegypti mosquitoes. With the aim of promoting products of plant origin as a viable alternative to conventional synthetic substances, this study was designed to transform AHE-based repellents for exploitable commercial production by enhancing their efficacy and assessing their physical and biological stability as well as repellency against mosquitoes under laboratory and field conditions.MethodsThe chemical profile of AHE was analyzed by qualitative gas chromatography-mass spectrometry (GC-MS) technique. AHE was supplemented with vanillin, as a fixative, and then investigated for repellency and comparison to the standard synthetic repellent, DEET, under both laboratory and field conditions. Determination of physical and biological stability as a repellent was carried out after keeping AHE samples under varying temperatures and for different storage times.ResultsGC-MS analysis revealed that AHE contained at least 21 phytochemical compounds, constituting 95.74 % of the total content, with the major constituent of 3- N -butylphthalide (66.67 %). Ethanolic formulations of AHE and DEET showed improvement of repellency in a dose-dependent manner when vanillin was added in laboratory assessment. While 5–25 % AHE alone provided median complete-protection times of 2.0–6.5 h against Ae. aegypti , these times were increased to 4.0–8.5 h with a combination of AHE and 5 % vanillin (AHEv). Protection times against Ae. aegypti were extended from 2.25 to 7.25 h to 4.25–8.25 h when 5–25 % DEET was combined with 5 % vanillin (DEETv). In determining stability, all stored AHE samples exhibited similar characteristics such as liquid phases with aromatic odor comparable to those of fresh preparations. Furthermore, repellent activity of stored AHE samples lasted for at least six months, with varied efficacy (4.5–10.0 h) against Ae. aegypti . Field trials revealed strong repellency from both 25 % AHEv and 25 % DEETv, with complete protection (100 %) against a wide range of Local mosquito populations. A total of 5,718 adult female mosquitoes, with the most predominant being Culex quinquefasciatus (41.47 %), Armigeres subalbatus (41.13 %), and Culex vishnui (10.53 %), was collected during field applications. No Local Skin Reaction or other allergic responses was observed during both laboratory and field study periods.ConclusionsAngelica sinensis proved to have not only impressive repellency against both laboratory Ae. aegypti and a wide range of natural mosquito populations, but also relative stability in physical and biological performance.
Shelbi Jim C On - One of the best experts on this subject based on the ideXlab platform.
-
relationship between severity of the Local Skin Reactions and the rate of Local Skin Reaction resolution in patients treated with ingenol mebutate gel
Clinical Cosmetic and Investigational Dermatology, 2016Co-Authors: Shelbi Jim C On, Kim Mark Knudsen, Torsten Skov, Mark LebwohlAbstract:BACKGROUND: Ingenol mebutate gel is a topical field treatment for actinic keratosis (AK). The treatment elicits application-site Reactions in most patients. This analysis evaluated the relationship between the severity of Reactions and the speed of their resolution. METHODS: Patients in Phase III studies were treated for AKs on the face (n=218), scalp (n=56), and trunk and extremities (n=209). All of the patients were treated with either ingenol mebutate gel 0.015% once daily for three consecutive days (face/scalp) or ingenol mebutate gel 0.05% once daily for two consecutive days (trunk/extremities). Local Skin Reactions (LSRs) were assessed on a 5-point scale from 0 to 4 in six categories, yielding composite scores in the range of 0 to 24. RESULTS: The composite LSR score on the day after the last application of ingenol mebutate gel was an important predictor of the speed of resolution of LSRs. The rate of resolution was greatest for AKs treated on the face, followed by the scalp, and then the trunk and extremities. All patients were expected to have minimal LSR scores for the face and scalp at 2 weeks, and for the trunk and extremities at 4 weeks. CONCLUSION: The absolute reduction in LSR scores was proportional to the composite LSR score on the day after the last application of ingenol mebutate gel treatment. The rate of resolution for LSRs was dependent on the anatomic site treated as well as the day 4 composite score.
